New Recommendations for Weight Loss Drugs

- Novo Nordisk’s Wegovy won U.S. approval in June 2021 with a label that says it can be used for chronic weight management in patients with a body mass index of 27 or more who have at least one weight-related ailment, or in any patient with a BMI of 30 or greater.

Obesity Canada: Updated its standards of care document in October 2022 to include use of semaglutide, the chemical name for Wegovy, and a related diabetes drug. These guidelines say doctors should tailor treatments to individuals using nutrition, physical activity, psychological interventions, medications, and surgery, and that BMI is not an accurate tool to identify obesity-related ailments. They also say drugs can be used to maintain weight loss that has been achieved by behavioral changes.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Long-Lasting Impact: Losing Weight May Benefit Your Heart, Even if Some Weight Is RegainedAccording to a research review published in Circulation: Cardiovascular Quality and Outcomes, the cardiovascular benefits of weight loss achieved through lifestyle changes were sustained for at least five years. Weight loss was associated with decreased risk factors for cardiovascular disease a
Source: SciTechDaily1 - 🏆 84. / 68 Read more »